Tubulysins are highly toxic tubulin-targeting agents with a narrow therapeutic window that are interesting for application in antibody-drug-conjugates (ADCs). For full control over drug-antibody ratio (DAR) and the effect thereof on pharmacokinetics and tumor targeting, a dual-labeling approach was developed, wherein the drug, tubulysin variants, and the antibody, the anti-HER2 monoclonal antibody (mAb) trastuzumab, are radiolabeled.
was 45 to 55% efficient, resulting in ADCs with 96 to 98% radiochemical purity after size-exclusion chromatography. ADCs were evaluated for their tumor-targeting potential and antitumor effects in nude mice with tumors that were sensitive or resistant to trastuzumab, using ado-trastuzumab emtansine as a reference. ADCs appeared stable in vivo. An average DAR of 2 and 4 conferred pharmacokinetics and tumor-targeting behavior similar to parental trastuzumab. Efficacy studies using single-dose TUB-OMOM-trastuzumab (DAR 4) showed dose-dependent anti-tumor effects, including complete tumor eradications in trastuzumab-sensitive tumors in vivo. TUB-OMOM-trastuzumab (60 mg/kg) displayed efficacy similar to ado-trastuzumab emtansine (15 mg/kg) yet more effective than trastuzumab. Our findings illustrate the potential of synthetic tubulysins in ADCs for cancer treatment.
INTRODUCTION
Continuing increases in the incidence of cancer, coupled with the limitations of traditional chemotherapy, such as systemic toxicity and rapid development of multidrug resistance 1 , have made the development of new therapeutic strategies a high priority. One of the most promising recent developments is targeted therapy, where drugs or other compounds are used that specifically interfere with targets involved in tumor growth and progression. Monoclonal antibodies (mAbs) are a good example of targeted therapy and can also be used as a vehicle for toxic compounds, to form antibody-drug-conjugates (ADCs) 2 . The ideal ADC allows application of highly toxic compounds otherwise having exceedingly narrow therapeutic windows and exhibits higher tumor toxicity than current chemotherapeutics 3 . In this context, the chemical synthesis of naturally occurring highly potent compounds and their derivatives becomes an important topic in ADC development. A very promising family of such compounds is represented by the tubulysins, which are tetrapeptides produced in small quantities by myxobacteria strains. The cytotoxic activity of tubulysins stems from their ability to inhibit tubulin polymerization and to disintegrate microtubules of dividing cells. Naturally occurring tubulysins have IC 50 values between 0.01 and 10 nmol/L and can be chemically synthesized 4 (for a comprehensive list of references see ref. 5) . Over the last decade, various tubulysin analogues with different cytotoxic potency were synthesized 5, 6 . Pre-clinical studies showed that tubulysins are too toxic for use as single-agent chemotherapeutics 7 and therefore targeted therapy becomes an appealing option to enable the administration of higher doses of tubulysins thus avoiding or minimizing systemic toxicity. Combining targeted therapy of mAbs with toxic agents might in fact result in highly specific and well-tolerated ADCs 8 .
Over the last few years, several ADCs have entered phase II/III clinical trials. Two of these, brentuximab vedotin and ado-trastuzumab emtansine (Adcetris and Kadcyla = T-DM1), are U.S. Food and Drug Administration (FDA)-approved and are now used to treat patients with Hodgkin's disease and HER2+ (human epidermal growth factor receptor 2) metastatic breast cancer, respectively. These and most of the other ADCs still in development consist of chimeric, humanized or fully human mAbs conjugated to tubulin-targeting inhibitors or DNA-damaging agents 9 .
Most ADCs consist of three components: the mAb, the toxic compound and a linker that combines the two parts. Three types of linkers are used to couple the mAb and the toxic compound: releasable, cleavable and noncleavable linkers 10 . Releasable linkers form a relatively stable ADC in serum and release the drug upon internalization in the cell. Accordingly, selective tumor release is due to the difference in composition between plasma and cytosol. Examples of releasable linkers are hydrazones and disulfides [11] [12] [13] [14] . ADCs containing a cleavable linker are about 100 times more stable in serum compared with ADCs with a releasable linker. An example is the peptide based p-aminobenzyl carbamate linker, which is used in the clinically available ADC brentuximab vedotin 15, 16 . Noncleavable linkers result in the most stable ADCs. Only upon internalization of the complete ADC and after degradation of the mAb the toxic part including an amino acid residue is released and can become active. Thioether bonds formed from SMCC [succinimidyl-4-(Nmaleimidomethyl)cyclohexane-1-carboxylate] are reported to be noncleavable linkers. Ado-trastuzumab emtansine contains this SMCC-based linker and was proven to give the best efficacy and lowest systemic toxicity compared with analogues with cleavable linkers 12 . For testing the highly potent tubulysins in an ADC, we chose to use the reliable and commonly used mAb trastuzumab (Herceptin) as the model mAb. Trastuzumab is a humanized anti-HER2 mAb directed against the extracellular domain of HER2, and treatment with this mAb is the standard of care as adjuvant treatment in patients with HER2-positive primary breast cancer and first and following lines of metastatic breast cancer. In view of the extreme toxicity of tubulysins, we regard a stable, noncleavable linkage mandatory. Because we and others 17, 18 have shown that the thioether bond is not such a nocleavable bond as presumed, we chose not to use a linker and opted for a non-cleavable bond that has found multiple applications in the clinic 17, 19 , namely a direct amide bond formation of tubulysins with lysine residues of the mAb. In fact, tubulysins possess a C-terminal carboxylic acid group enabling direct coupling with these lysine residues after conversion to an active ester.
Before an ADC can be used in in vivo experiments, the stability of the conjugate must be confirmed. Also, knowledge of the pharmacokinetics can be informative for future development. For a thorough study of the targeting behavior of the ADCs and their in vitro and in vivo stability, and to facilitate monitoring of conjugation and purification procedures we decided to radiolabel the tubulysin analogues as well as the mAb. In the present study, we describe the 131 I-radioiodination of two synthetic tubulysin A analogues, the less potent TUB-OH and the potent TUB-OMOM, and the conjugation of these 131 I-labeled tubulysins to non-labeled or 89 Zr-labeled trastuzumab (Figure 1) . The obtained ADCs were evaluated in vitro for effects on cell viability, and in vivo for their pharmacokinetic behavior and tumor-targeting potential. After determination of the maximum-tolerated dose (MTD), antitumor effects of the most potent ADC were tested in nude mice bearing trastuzumab-resistent JIMT or trastuzumab-sensitive N87 tumors using adotrastuzumab emtansine as reference.
MATERIALS AND METHODS

General materials and methods
Cell lines used were the breast cancer lines MDA-MB231, JIMT and SKBR3, the ovarian cancer cell line SKOV, and the gastric cancer cell line N87. JIMT-1 was obtained from DSMZ Germany on March 19, 2012, after cytogenetic testing, and used within 6 months after resuscitation. NCI-N87 was obtained from ATCC United Kingdom on February 29, 2012, after cytogenetic testing, and used within 6 months after resuscitation. SKBR3 was obtained from Dr. T. Oude Munnink (Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands), MDA-MB-231 from Roche, and SK-OV-3 from the Department of Medical Oncology, VU University Medical Center Amsterdam. All cell lines were checked for primary growth characteristics (morphology and growth rate) and HER2 expression. MDA-MB231 is a cell line with low HER2-expression; SKBR3, SKOV, and N87 are overexpressing HER2; and JIMT is developed from tumor cells of a patient with trastuzumab resistance and is HER2-positive 20 
Preparation of single-and dual-labeled ADCs
Trastuzumab (2 mg, 95 µL; 13.3 nmol; 21 mg/mL) was mixed with 0.9% sodium chloride (900 µL) and 50 mmol/L Na 2 CO 3 (7 µL) after which 4 or 8 equivalents (eq; 53 or 106 nmol) of I-TUB-OMOM-trastuzumab containing on average either two or four tubulysin molecules per mAb molecule (2 eq, respectively, 4 eq), was purified using a PD-10 column (GE Healthcare) or HiTrap Desalting Column (GE Healthcare). Protein concentration was determined by HPLC using a calibration curve of trastuzumab. Instant thin layer chromatography (iTLC) analysis of the ADCs was carried out to assess the conjugation efficiency and radiochemical purity of the ADC. Silica impregnated glass fiber sheets (PI Medical Diagnostic Equipment BV, Tijnje, The Netherlands) were used with 20 mmol/L citrate buffer (pH 5.0)/MeOH (3/7) as the mobile phase. As readout gamma-well counting or phosphor imager analysis (FLA 8000, GE) followed by quantification with ImageQuant software was used.
Dual labeled
Zr-trastuzumab was obtained from 89 Zr-labeled trastuzumab (2 mg in 1 mL 0.9% NaCl, 13.3 nmol, 3.2 MBq 89 Zr) following exactly the same procedure as described above. Premodification of trastuzumab (5 mg, Df/ mAb molar ratio 0.5) and labeling with 89 Zr (10 MBq) was performed according to part 1 and 3 of the protocols described by Cohen and collegues 21 . I-TUB-OMOM-trastuzumab were stored at 4°C in 0.9% NaCl and at 37°C in 0.9% NaCl or 60% human serum. At different time points, radiochemical purity of the conjugates was measured by iTLC, while conjugate integrity was analyzed by SDS-PAGE followed by phosphor imager analysis. For SDS-PAGE, samples were mixed 1:1 with loading buffer and run on a Phastgel System (GE Healthcare Life Sciences) using preformed 7.5% SDS-PAGE gels under non-reducing conditions. The gel was analyzed using a phosphor imager and quantified with ImageQuant software. In vitro binding characteristics of the ADCs were determined in an immunoreactivity assay essentially as described by Lindmo and collegues 22 , using a serial dilution of 0.2% glutaraldehyde-fixed N87 cells and a fixed amount of ADC 131 I-TUB-OH-trastuzumab or 131 I-TUB-OMOM-trastuzumab (5-15 ng). After overnight incubation at 4°C, the cell suspension was centrifuged and the specific binding calculated as the ratio of cell-bound radioactivity to the total amount of radioactivity in the assay. This was corrected for non-specific binding, as determined with a 500-fold excess of non-radioactive trastuzumab. All binding assays were performed in triplicate.
Stability and in vitro cell binding of the ADCs
In vitro cell viability assay
The effects of the tubulysins TUB-OH and TUB-OMOM, the ADCs Zr-trastuzumab (100 µg mAb). At 3, 24, 48 or 72 hours after injection the mice were anesthetized, bled, euthanized and dissected. Blood and organs were weighed, and further processed as described above.
To evaluate the biodistribution of unconjugated tubulysin, 8 mice were injected (i.v.) with 0.12 MBq I-TUB-OMOM-trastuzumab, 2 eq). After 1, 2, 3 and 24 hours, 2 mice were anesthetized, bled, euthanized and dissected and further processed as described above.
In vivo MTD and therapy study
Before starting the therapy study, the MTD for TUB-OMOM-trastuzumab was determined. For this purpose, 5 groups of 5 nude mice were given 15, 30, 45 or 60 mg/kg trace-dose labeled 131 I-TUB-OMOM-trastuzumab (4 eq) or normal saline as a control by an i.p bolus injection. Trace-dose labeling in this and subsequent experiments was only used to confirm tubulysin-to-mAb molar ratio. Body weight was measured 3 times per week and MTD was reached when weight loss was >10% compared to the control mice.
The therapeutic effectiveness of trace-dose labeled 131 I-TUB-OMOM-trastuzumab (4 eq) was studied in the same nude mice models as described for the biodistribution study. For this purpose, six groups of 7 mice with established JIMT or N87 xenografts in both flanks were used. The mean tumor size at the start of the study was 85 ± 15 mm 
Statistical analysis
All animal experiments were statistically analyzed with SPSS, version 21 (SPSS Inc.) using the Student t test for independent samples. Two-sided significance levels were calculated, and P < 0.05 was considered statistically significant.
RESULTS
Effects of TUB-OH and TUB-OMOM on in vitro cell viability
The toxicity of TUB-OH and TUB-OMOM was determined in CellTiter-Blue assays. Five different cell lines were incubated with TUB-OH or TUB-OMOM for 5 days. The HER2-overexpressing cell lines N87, SKBr3 and SKOV, the trastuzumabresistant cell line JIMT, and the HER2-negative cell line MDA-MB231 were found to be relatively insensitive to TUB-OH (Supplementary Figure S1A) , the corresponding IC 50 's are >100 nmol/L. However, TUB-OMOM (Supplementary Figure S1B) showed IC 50 values between 0.4 and 6 nmol/L.
Preparation of radioiodinated tubulysin esters and their corresponding ADCs
The tubulysin analogues TUB-OH and TUB-OMOM are poorly soluble in aqueous solution and required the addition of MeCN to obtain a homogeneous solution.
Radioiodination was carried out with [ 131 I]iodide, using chloramine-T as oxidant.
The reaction depicted in I-TUB-OMOM-NHS with a conversion >99% (Figure 2A) . Via an inverted Seppak tC2 Light purification I-TUB-OMOM-trastuzumab before (1) and after (2) purification. Conjugation efficiency in this example was 47% (1) and radiochemical purity of the final product 97% (2). C, the HPLC chromatogram of purified 131 I-TUB-OMOM-trastuzumab for UV (upper channel) and radioactivity (lower channel); retention time of the ADC was 26 min. procedure, the radioiodinated tubulysin esters were isolated in 68 ± 5% overall yield with a radiochemical purity of >99.5 %. The NHS-esters were stored in a glass vial at -80°C as a MeCN solution at a concentration of 5.3 nmol/µL. Esters were produced with three different 131 I-specific activities, namely 114 ± 6, 57 ± 3, and 6 ± 1 kBq/nmol.
For Figure 2B ). Longer reaction times did not increase conjugation efficiency. Purification of the ADC was performed using size exclusion chromatography and resulted in a radiochemical purity of 96% to 98% (PD10 columns or HiTrap Desalting columns; Figure 2B , C).
In vitro stability and effects on cell viability of ADCs
The stability of the ADCs was determined at 4°C in 0.9% aqueous NaCl and at 37°C in 60% human serum (0.9% NaCl included for comparison) by iTLC. At time point t = 0, immediately after filtration of the product, the radiochemical purity of the samples was 98% under both conditions. After 5 days in NaCl at 4°C, no additional release of 131 I was detected, whereas in serum samples and NaCl at 37°C, an additional 3% to 4% release of 131 I was observed. Lindmo assays showed at t = 0 a maximum binding between 93% and 96% to N87 cells. After 5 days the binding assay showed a decrease of maximum binding to 89% to 92%. However, Figure S2) . These data indicate that coupling of tubulysins (2 eq) does not alter pharmacokinetics of trastuzumab, and that conjugates are stable in vivo in blood.
For a more detailed study of the effect of tubulysin coupling on pharmacokinetics and tumor targeting, N87 and JIMT tumor-bearing mice were injected with duallabeled 131 I-TUB-OMOM- did not show significant differences in blood levels as well as tumor uptake levels when compared with unconjugated I-TUB-OMOM shows rapid blood clearance and predominant accumulation in the colon and ileum content.
In vivo MTD and therapy study
A MTD study was performed to determine the maximum tolerated dose of TUB-OMOM-trastuzumab (4 eq). Non-tumor bearing mice were injected with 15, 30, 45 or 60 mg/kg, single bolus injection. No weight loss or other signs of toxicity were observed. Next, the in vivo efficacy of different doses of TUB-OMOM-trastuzumab was compared with trastuzumab and ado-trastuzumab emtansine in JIMT-and N87-tumor-bearing mice. JIMT tumors showed no significant growth delay when injected with 15, 30 or 60 mg/kg TUB-OMOM-trastuzumab or 15 mg/kg adotrastuzumab emtansine compared to the mice injected with trastuzumab alone (Supplementary Figure S5) . Figure 6 shows that mice with N87 tumors responded when injected with trastuzumab, but to a distinct lesser extent than after injection of the ADCs. Tumor response upon treatment with TUB-OMOM-trastuzumab was dose dependent with the highest dose, 60 mg/kg, showing the same effect as adotrastuzumab emtansine, 15 mg/kg. Cures, defined as no outgrowth of regressed individual tumors during the follow-up period, were seen in mice treated with 30 mg/kg TUB-OMOM-trastuzumab (n = 1), 60 mg/kg TUB-OMOM-trastuzumab (n = 3) and 15 mg/kg ado-trastuzumab emtansine (n = 3).
DISCUSSION
Stability in blood is a prerequisite in the development of ADCs when highly toxic compounds like tubulysins are used, because sequestration of the free drug in normal organs might cause unacceptable toxicity. In addition, it is important to determine if the tumor-targeting capacity of a mAb is preserved upon coupling of such drugs and to gain knowledge on antitumor effects as efficacy strongly depends on ADC internalization and intracellular processing. Most studies focus on the antitumor effects of the ADC, while neglecting thorough characterization of the ADC in vivo. The easiest way to get this information is by using a strategy of dual-radiolabeling in which drug and mAb each receive a different radiolabel.
In this study we developed procedures to radiolabel the less potent TUB-OH (IC 50 > 100 nM) and the potent TUB-OMOM (IC 50 0.4-6 nM) with 131 I, to convert them to an active NHS ester, and to couple the esters successfully to unlabeled or 89 Zr-labeled trastuzumab. Conversion of the 131 I-labeled tubulysins to the NHS esters was >99%, while the esters were isolated at an overall yield of 68 ± 5% and a radiochemical purity of >99.5%. Conjugation of the 131 I-tubulysin esters to unlabeled or 89 Zr-labeled trastuzumab antibody was 45% to 55% efficient. Because all tubulysin analogues possess a C-terminal carboxylic acid group, the conjugation procedure developed herein is generally applicable for the production of tubulysin ADCs. Radiochemical purity of the radiolabeled ADCs was 96% to 98%, which leaves room for improvement when tubulysin-antibody conjugates are prepared for clinical application. Several radioiodination and esterification routes were explored before arriving at the current procedure. The described mild radioiodination route makes use of chloramine-T as the oxidant, the presence of MeCN in the reaction mixture prohibited the use of Iodogen-coated vials 24 . The tubulysins required the presence of a free phenol group on the C-terminal amino acid fragment, tubulysins with a methoxyphenyl group could not be radioiodinated.
131
I-TUB-OH and TUB-OMOM were reacted with NHS, sulfoNHS, and TFP-OH, only the NHS ester could be efficiently formed and purified by Seppak. The TFP-ester did not elute from the Seppak (too apolar) and sulfoNHS-ester was not trapped on the Seppak (too polar). The radioiodine label also revealed that upon purification with size exclusion chromatography, about 2% to 4% of non-conjugated tubulysin coeluted with the ADC, possibly because of trapping in the tertiary structure of the mAb molecule. Figure S2) showed no significant differences.
I-TUB-OH-trastuzumab (Supplementary
The hydrophobicity of a coupled drug, as well as the type, number, and arrangement of charged groups, can strongly influence the physicochemical properties of the mAb, resulting in extended aggregation, altered pharmacokinetics and impairment of tumor targeting, even when the in vitro antigen binding of the mAb remains preserved [26] [27] [28] . For this reason, conjugation procedures are currently introduced that give optimal control over the number of drug molecules coupled to the mAb as well as the mAb sites for drug coupling [29] [30] [31] . In our studies, 0, 2, or 4 equivalents of 131 I-TUB-OMOM on average were directly coupled to the lysine residues of 89 Zrtrastuzumab, avoiding premodification of the mAb as in case of ado-trastuzumab I were also observed in normal tissues. Whether this is the result of intra-and/or extracellular degradation of the ADC is subject of further investigations.
In vivo therapy studies with a single dose of TUB-OMOM-trastuzumab showed dose-dependent antitumor effects in established N87 tumor bearing mice. The highest dose, 60 mg/kg, exhibited the same effect as ado-trastuzumab emtansine (15 mg/ kg) and a more pronounced effect than trastuzumab alone. No weight loss or other signs of toxicity occurred. Complete eradication of N87 tumors was observed with 30 mg/kg TUB-OMOM-trastuzumab (n = 1), 60 mg/kg TUB-OMOM-trastuzumab (n = 3), and 15 mg/kg ado-trastuzumab emtansine (n = 3). Neither TUB-OMOMtrastuzumab nor ado-trastuzumab emtansine caused anti-tumor effects in mice bearing the JIMT xenograft line, despite the fact that TUB-OMOM-trastuzumab is targeting JIMT and N87 tumors equally well (see Figure 4 and Supplementary Figure S3) . The ADC is degraded more rapidly in JIMT tumors than in N87 tumors, resulting in release of 131 I from the tumor, and this might be one of the reasons why JIMT tumors show resistance. To get more insight in drug degradation, LC/ MS-MS procedures for tubulysin metabolite analysis in tumors are currently being developed.
The use of radiolabeling strategies not only has value for the development and preclinical validation of ADCs as shown herein, but also might be of help during the clinical development of ADCs. The potential of positron emission tomography (PET) imaging of 89 Zr-labeled antibodies (i.e., 89 Zr-immuno-PET) in mAb development and applications has been shown for several mAbs directed against growth factors and membrane receptors 33, 34 , the HER2 receptor included 35 . 89 Zr-immuno-PET can learn about the ideal mAb dosing for optimal tumor targeting (e.g., saturation of receptors), the uptake in critical normal tissues to anticipate toxicity, and the interpatient variation in pharmacokinetics and tumor targeting. In analogy, 89 Zr-immuno-PET might be supportive in the clinical development of tubulysinantibody conjugates.
In conclusion, herein we show for the first time the potential of tubulysin-antibody conjugates for cancer treatment, thus opening new avenues in ADC development. Nowadays, fully synthetic tubulysins can be produced on large scale and with a broad chemical diversity 5, 6 , resulting in higher potency and chemical stability relative to the natural compounds. Some of these synthetic tubulysins derivatives are 10 to 100 times more potent in vitro than the TUB-OMOM as used in the present study (unpublished data). Direct coupling of these tubulysin derivatives to lysine residues of mAbs, via the straightforward method reported here, might result in ADCs more potent than TUB-OMOM-trastuzumab and ado-trastuzumab emtansine. In future strategies for TUB-mAb production, conjugation efficiency can easily be monitored by protein mass spectrometry instead of by use of radioactivity 36, 37 . 
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